The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report 2024
Synopsis
The global Paroxysmal Nocturnal Hemoglobinuria Treatment market was valued at US$ 3324.1 million in 2023 and is anticipated to reach US$ 5939.2 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Treatment.
Report Scope
The Paroxysmal Nocturnal Hemoglobinuria Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Paroxysmal Nocturnal Hemoglobinuria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paroxysmal Nocturnal Hemoglobinuria Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Regenesance BV
Segment by Type
ACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Paroxysmal Nocturnal Hemoglobinuria Treatment market was valued at US$ 3324.1 million in 2023 and is anticipated to reach US$ 5939.2 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Treatment.
Report Scope
The Paroxysmal Nocturnal Hemoglobinuria Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Paroxysmal Nocturnal Hemoglobinuria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paroxysmal Nocturnal Hemoglobinuria Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Regenesance BV
Segment by Type
ACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ACH-4471
1.2.3 ALN-CC5
1.2.4 ALXN-1210
1.2.5 AMY-101
1.2.6 APL-2
1.2.7 Others
1.3 Market by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Perspective (2019-2030)
2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Trends by Region
2.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Region (2019-2024)
2.2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Region (2025-2030)
2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Dynamics
2.3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Trends
2.3.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
2.3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
2.3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue
3.1.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue (2019-2024)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue
3.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio
3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2023
3.5 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players Head office and Area Served
3.6 Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Product Solution and Service
3.7 Date of Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Type (2019-2024)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2025-2030)
5 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Application (2019-2024)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2019-2030)
6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2019-2024)
6.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2019-2030)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2019-2024)
7.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2019-2030)
8.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2019-2030)
9.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2019-2024)
9.4 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2019-2030)
10.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Achillion Pharmaceuticals Inc
11.1.1 Achillion Pharmaceuticals Inc Company Detail
11.1.2 Achillion Pharmaceuticals Inc Business Overview
11.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.1.5 Achillion Pharmaceuticals Inc Recent Development
11.2 Akari Therapeutics Plc
11.2.1 Akari Therapeutics Plc Company Detail
11.2.2 Akari Therapeutics Plc Business Overview
11.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.2.5 Akari Therapeutics Plc Recent Development
11.3 Alexion Pharmaceuticals Inc
11.3.1 Alexion Pharmaceuticals Inc Company Detail
11.3.2 Alexion Pharmaceuticals Inc Business Overview
11.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.3.5 Alexion Pharmaceuticals Inc Recent Development
11.4 Alnylam Pharmaceuticals Inc
11.4.1 Alnylam Pharmaceuticals Inc Company Detail
11.4.2 Alnylam Pharmaceuticals Inc Business Overview
11.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.4.5 Alnylam Pharmaceuticals Inc Recent Development
11.5 Amgen Inc
11.5.1 Amgen Inc Company Detail
11.5.2 Amgen Inc Business Overview
11.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.5.5 Amgen Inc Recent Development
11.6 Apellis Pharmaceuticals Inc
11.6.1 Apellis Pharmaceuticals Inc Company Detail
11.6.2 Apellis Pharmaceuticals Inc Business Overview
11.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.6.5 Apellis Pharmaceuticals Inc Recent Development
11.7 F. Hoffmann-La Roche Ltd
11.7.1 F. Hoffmann-La Roche Ltd Company Detail
11.7.2 F. Hoffmann-La Roche Ltd Business Overview
11.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.7.5 F. Hoffmann-La Roche Ltd Recent Development
11.8 ISU ABXIS Co Ltd
11.8.1 ISU ABXIS Co Ltd Company Detail
11.8.2 ISU ABXIS Co Ltd Business Overview
11.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.8.5 ISU ABXIS Co Ltd Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Detail
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.9.5 Novartis AG Recent Development
11.10 NovelMed Therapeutics Inc
11.10.1 NovelMed Therapeutics Inc Company Detail
11.10.2 NovelMed Therapeutics Inc Business Overview
11.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.10.5 NovelMed Therapeutics Inc Recent Development
11.11 Omeros Corp
11.11.1 Omeros Corp Company Detail
11.11.2 Omeros Corp Business Overview
11.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.11.5 Omeros Corp Recent Development
11.12 Ra Pharmaceuticals Inc
11.12.1 Ra Pharmaceuticals Inc Company Detail
11.12.2 Ra Pharmaceuticals Inc Business Overview
11.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.12.5 Ra Pharmaceuticals Inc Recent Development
11.13 Regeneron Pharmaceuticals Inc
11.13.1 Regeneron Pharmaceuticals Inc Company Detail
11.13.2 Regeneron Pharmaceuticals Inc Business Overview
11.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.13.5 Regeneron Pharmaceuticals Inc Recent Development
11.14 Regenesance BV
11.14.1 Regenesance BV Company Detail
11.14.2 Regenesance BV Business Overview
11.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2019-2024)
11.14.5 Regenesance BV Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
